{"id":22733,"date":"2024-02-19T13:19:37","date_gmt":"2024-02-19T12:19:37","guid":{"rendered":"https:\/\/ggba.swiss\/alys-pharmaceuticals-launches-in-geneva-with-usd-100-million-investment\/"},"modified":"2024-02-19T13:21:55","modified_gmt":"2024-02-19T12:21:55","slug":"alys-pharmaceuticals-se-lance-a-geneve-avec-un-investissement-de-usd-100-millions","status":"publish","type":"post","link":"https:\/\/ggba.swiss\/fr\/alys-pharmaceuticals-se-lance-a-geneve-avec-un-investissement-de-usd-100-millions\/","title":{"rendered":"Alys Pharmaceuticals se lance \u00e0 Gen\u00e8ve avec un investissement de USD 100 millions"},"content":{"rendered":"\n<p><a href=\"https:\/\/alyspharma.com\/\">Alys Pharmaceuticals<\/a> est n\u00e9e de la consolidation d&rsquo;Aldena Therapeutics, de Granular Therapeutics, de Klirna Biotech &#8211; qui poss\u00e8de des activit\u00e9s et un personnel importants en Suisse -, de Graegis Pharmaceuticals, de Nira Biosciences et de Vimela Therapeutics. Cette fusion strat\u00e9gique permet \u00e0 Alys de disposer de 14 programmes actifs pr\u00eats \u00e0 r\u00e9aliser des perc\u00e9es en dermatologie, en particulier dans des domaines tels que la dermatite atopique, le vitiligo et d&rsquo;autres encore.<\/p>\n\n\n\n<p>Ce g\u00e9ant de la biotechnologie ne se contente pas de disposer d&rsquo;un formidable pipeline, il souhaite \u00e9galement \u00e9largir son portefeuille gr\u00e2ce \u00e0 des plateformes innovantes couvrant les maladies inflammatoires et auto-immunes, les soins de soutien en dermatologie pour les patients atteints de cancer et les dermatoses rares. Au cours des trois prochaines ann\u00e9es, Alys vise \u00e0 atteindre sept \u00e0 dix r\u00e9sultats cliniques de preuve de concept, avec au moins un programme progressant vers des \u00e9tudes d&rsquo;enregistrement.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\">\u00c0 la pointe de l&rsquo;innovation dermatologique<\/h4>\n\n\n\n<p>Avec un investissement substantiel de USD 100 millions de <a href=\"https:\/\/www.medicxi.com\/\">Medicxi<\/a>, Alys, \u00e0 cheval entre Boston et Gen\u00e8ve, est pr\u00eate \u00e0 red\u00e9finir le traitement dermatologique dans plusieurs domaines. Une grande partie des activit\u00e9s de l&rsquo;entreprise se d\u00e9roulera en Suisse et comprendra un large \u00e9ventail de travaux biotechnologiques allant de la R&amp;D aux affaires r\u00e9glementaires. Aldena Therapeutics, une filiale d&rsquo;Alys, collabore avec l&rsquo;<a href=\"https:\/\/www.empa.ch\/web\/empa\/home\">EMPA<\/a> dans le cadre d&rsquo;une bourse Innosuisse pour faire progresser des technologies de base. En outre, l&rsquo;\u00e9quipe suisse d&rsquo;Alys, qui devrait s&rsquo;\u00e9toffer au fur et \u00e0 mesure de l&rsquo;avancement des programmes, est renforc\u00e9e par des consultants locaux et des soci\u00e9t\u00e9s de services en recherche et d\u00e9veloppement.<\/p>\n\n\n\n<p>La cr\u00e9ation d&rsquo;Alys est le fruit de l&rsquo;imagination de Medicxi, aux c\u00f4t\u00e9s de sommit\u00e9s de la dermatologie telles que John Harris, Brian Kim et Craig Mello, laur\u00e9at du prix Nobel, entre autres. Francesco De Rubertis, partenaire de Medicxi et nouveau pr\u00e9sident d&rsquo;Alys, a salu\u00e9 la fusion, soulignant l&rsquo;avantage strat\u00e9gique que repr\u00e9sente la mise en commun d&rsquo;actifs divers et la facilitation de l&rsquo;acc\u00e8s au capital. Cette fusion ne marque pas seulement un nouveau chapitre dans le domaine de l&rsquo;immuno-dermatologie, mais consolide \u00e9galement la position de Gen\u00e8ve en tant que plaque tournante mondiale de la biotechnologie.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Alys Pharmaceuticals, une entit\u00e9 biotechnologique nouvellement cr\u00e9\u00e9e, fusionne les comp\u00e9tences de six entreprises biotech de Medicxi pour \u00eatre un fer de lance de l&rsquo;innovation dans le domaine de l&rsquo;immunodermatologie.<\/p>\n","protected":false},"author":6,"featured_media":22730,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"mc4wp_mailchimp_campaign":[],"footnotes":""},"categories":[843],"tags":[1169,1188,1154,1141],"class_list":["post-22733","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-sciences-de-la-vie","tag-biotech-fr-2","tag-healthcare-fr-2","tag-investment-fr-2","tag-personalized-medicine-fr-2"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Alys se lance \u00e0 Gen\u00e8ve avec un investissement de USD 100M<\/title>\n<meta name=\"description\" content=\"Alys Pharmaceuticals fusionne les comp\u00e9tences de six entreprises biotech de Medicxi pour innover dans le domaine de l&#039;immunodermatologie.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ggba.swiss\/fr\/alys-pharmaceuticals-se-lance-a-geneve-avec-un-investissement-de-usd-100-millions\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Alys se lance \u00e0 Gen\u00e8ve avec un investissement de USD 100M\" \/>\n<meta property=\"og:description\" content=\"Alys Pharmaceuticals fusionne les comp\u00e9tences de six entreprises biotech de Medicxi pour innover dans le domaine de l&#039;immunodermatologie.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ggba.swiss\/fr\/alys-pharmaceuticals-se-lance-a-geneve-avec-un-investissement-de-usd-100-millions\/\" \/>\n<meta property=\"og:site_name\" content=\"Greater Geneva Bern area\" \/>\n<meta property=\"article:published_time\" content=\"2024-02-19T12:19:37+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-02-19T12:21:55+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ggba.swiss\/app\/uploads\/2024\/02\/Alys-Pharamceuticals-Shoulder-2360x1622-1-1024x704.jpeg\" \/>\n\t<meta property=\"og:image:width\" content=\"1024\" \/>\n\t<meta property=\"og:image:height\" content=\"704\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Pierre-Yves Oehrli\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"Pierre-Yves Oehrli\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/ggba.swiss\/fr\/alys-pharmaceuticals-se-lance-a-geneve-avec-un-investissement-de-usd-100-millions\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/alys-pharmaceuticals-se-lance-a-geneve-avec-un-investissement-de-usd-100-millions\/\"},\"author\":{\"name\":\"Pierre-Yves Oehrli\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\"},\"headline\":\"Alys Pharmaceuticals se lance \u00e0 Gen\u00e8ve avec un investissement de USD 100 millions\",\"datePublished\":\"2024-02-19T12:19:37+00:00\",\"dateModified\":\"2024-02-19T12:21:55+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/alys-pharmaceuticals-se-lance-a-geneve-avec-un-investissement-de-usd-100-millions\/\"},\"wordCount\":407,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/alys-pharmaceuticals-se-lance-a-geneve-avec-un-investissement-de-usd-100-millions\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2024\/02\/Alys-Pharamceuticals-Shoulder-2360x1622-1.jpeg\",\"keywords\":[\"Biotech\",\"Healthcare\",\"Investment\",\"Personalized Medicine\"],\"articleSection\":[\"Sciences de la vie\"],\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/ggba.swiss\/fr\/alys-pharmaceuticals-se-lance-a-geneve-avec-un-investissement-de-usd-100-millions\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/ggba.swiss\/fr\/alys-pharmaceuticals-se-lance-a-geneve-avec-un-investissement-de-usd-100-millions\/\",\"url\":\"https:\/\/ggba.swiss\/fr\/alys-pharmaceuticals-se-lance-a-geneve-avec-un-investissement-de-usd-100-millions\/\",\"name\":\"Alys se lance \u00e0 Gen\u00e8ve avec un investissement de USD 100M\",\"isPartOf\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/alys-pharmaceuticals-se-lance-a-geneve-avec-un-investissement-de-usd-100-millions\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/alys-pharmaceuticals-se-lance-a-geneve-avec-un-investissement-de-usd-100-millions\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2024\/02\/Alys-Pharamceuticals-Shoulder-2360x1622-1.jpeg\",\"datePublished\":\"2024-02-19T12:19:37+00:00\",\"dateModified\":\"2024-02-19T12:21:55+00:00\",\"author\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\"},\"description\":\"Alys Pharmaceuticals fusionne les comp\u00e9tences de six entreprises biotech de Medicxi pour innover dans le domaine de l'immunodermatologie.\",\"breadcrumb\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/alys-pharmaceuticals-se-lance-a-geneve-avec-un-investissement-de-usd-100-millions\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/ggba.swiss\/fr\/alys-pharmaceuticals-se-lance-a-geneve-avec-un-investissement-de-usd-100-millions\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/ggba.swiss\/fr\/alys-pharmaceuticals-se-lance-a-geneve-avec-un-investissement-de-usd-100-millions\/#primaryimage\",\"url\":\"https:\/\/ggba.swiss\/app\/uploads\/2024\/02\/Alys-Pharamceuticals-Shoulder-2360x1622-1.jpeg\",\"contentUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2024\/02\/Alys-Pharamceuticals-Shoulder-2360x1622-1.jpeg\",\"width\":2360,\"height\":1622,\"caption\":\"Ce soutien financier important souligne le potentiel du pipeline complet d'Alys, qui cible un large \u00e9ventail d'indications dermatologiques, de la dermatite atopique au psoriasis. | \u00a9 Alys Pharmaceuticals\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/ggba.swiss\/fr\/alys-pharmaceuticals-se-lance-a-geneve-avec-un-investissement-de-usd-100-millions\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/ggba.swiss\/fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Alys Pharmaceuticals se lance \u00e0 Gen\u00e8ve avec un investissement de USD 100 millions\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#website\",\"url\":\"https:\/\/staging.ggba.swiss\/en\/\",\"name\":\"Greater Geneva Bern area\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\",\"name\":\"Pierre-Yves Oehrli\",\"url\":\"https:\/\/ggba.swiss\/fr\/author\/pierre-yves-oehrli\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Alys se lance \u00e0 Gen\u00e8ve avec un investissement de USD 100M","description":"Alys Pharmaceuticals fusionne les comp\u00e9tences de six entreprises biotech de Medicxi pour innover dans le domaine de l'immunodermatologie.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ggba.swiss\/fr\/alys-pharmaceuticals-se-lance-a-geneve-avec-un-investissement-de-usd-100-millions\/","og_locale":"fr_FR","og_type":"article","og_title":"Alys se lance \u00e0 Gen\u00e8ve avec un investissement de USD 100M","og_description":"Alys Pharmaceuticals fusionne les comp\u00e9tences de six entreprises biotech de Medicxi pour innover dans le domaine de l'immunodermatologie.","og_url":"https:\/\/ggba.swiss\/fr\/alys-pharmaceuticals-se-lance-a-geneve-avec-un-investissement-de-usd-100-millions\/","og_site_name":"Greater Geneva Bern area","article_published_time":"2024-02-19T12:19:37+00:00","article_modified_time":"2024-02-19T12:21:55+00:00","og_image":[{"width":1024,"height":704,"url":"https:\/\/ggba.swiss\/app\/uploads\/2024\/02\/Alys-Pharamceuticals-Shoulder-2360x1622-1-1024x704.jpeg","type":"image\/jpeg"}],"author":"Pierre-Yves Oehrli","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"Pierre-Yves Oehrli","Dur\u00e9e de lecture estim\u00e9e":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ggba.swiss\/fr\/alys-pharmaceuticals-se-lance-a-geneve-avec-un-investissement-de-usd-100-millions\/#article","isPartOf":{"@id":"https:\/\/ggba.swiss\/fr\/alys-pharmaceuticals-se-lance-a-geneve-avec-un-investissement-de-usd-100-millions\/"},"author":{"name":"Pierre-Yves Oehrli","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41"},"headline":"Alys Pharmaceuticals se lance \u00e0 Gen\u00e8ve avec un investissement de USD 100 millions","datePublished":"2024-02-19T12:19:37+00:00","dateModified":"2024-02-19T12:21:55+00:00","mainEntityOfPage":{"@id":"https:\/\/ggba.swiss\/fr\/alys-pharmaceuticals-se-lance-a-geneve-avec-un-investissement-de-usd-100-millions\/"},"wordCount":407,"commentCount":0,"image":{"@id":"https:\/\/ggba.swiss\/fr\/alys-pharmaceuticals-se-lance-a-geneve-avec-un-investissement-de-usd-100-millions\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2024\/02\/Alys-Pharamceuticals-Shoulder-2360x1622-1.jpeg","keywords":["Biotech","Healthcare","Investment","Personalized Medicine"],"articleSection":["Sciences de la vie"],"inLanguage":"fr-FR","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/ggba.swiss\/fr\/alys-pharmaceuticals-se-lance-a-geneve-avec-un-investissement-de-usd-100-millions\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/ggba.swiss\/fr\/alys-pharmaceuticals-se-lance-a-geneve-avec-un-investissement-de-usd-100-millions\/","url":"https:\/\/ggba.swiss\/fr\/alys-pharmaceuticals-se-lance-a-geneve-avec-un-investissement-de-usd-100-millions\/","name":"Alys se lance \u00e0 Gen\u00e8ve avec un investissement de USD 100M","isPartOf":{"@id":"https:\/\/staging.ggba.swiss\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/ggba.swiss\/fr\/alys-pharmaceuticals-se-lance-a-geneve-avec-un-investissement-de-usd-100-millions\/#primaryimage"},"image":{"@id":"https:\/\/ggba.swiss\/fr\/alys-pharmaceuticals-se-lance-a-geneve-avec-un-investissement-de-usd-100-millions\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2024\/02\/Alys-Pharamceuticals-Shoulder-2360x1622-1.jpeg","datePublished":"2024-02-19T12:19:37+00:00","dateModified":"2024-02-19T12:21:55+00:00","author":{"@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41"},"description":"Alys Pharmaceuticals fusionne les comp\u00e9tences de six entreprises biotech de Medicxi pour innover dans le domaine de l'immunodermatologie.","breadcrumb":{"@id":"https:\/\/ggba.swiss\/fr\/alys-pharmaceuticals-se-lance-a-geneve-avec-un-investissement-de-usd-100-millions\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ggba.swiss\/fr\/alys-pharmaceuticals-se-lance-a-geneve-avec-un-investissement-de-usd-100-millions\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/ggba.swiss\/fr\/alys-pharmaceuticals-se-lance-a-geneve-avec-un-investissement-de-usd-100-millions\/#primaryimage","url":"https:\/\/ggba.swiss\/app\/uploads\/2024\/02\/Alys-Pharamceuticals-Shoulder-2360x1622-1.jpeg","contentUrl":"https:\/\/ggba.swiss\/app\/uploads\/2024\/02\/Alys-Pharamceuticals-Shoulder-2360x1622-1.jpeg","width":2360,"height":1622,"caption":"Ce soutien financier important souligne le potentiel du pipeline complet d'Alys, qui cible un large \u00e9ventail d'indications dermatologiques, de la dermatite atopique au psoriasis. | \u00a9 Alys Pharmaceuticals"},{"@type":"BreadcrumbList","@id":"https:\/\/ggba.swiss\/fr\/alys-pharmaceuticals-se-lance-a-geneve-avec-un-investissement-de-usd-100-millions\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ggba.swiss\/fr\/"},{"@type":"ListItem","position":2,"name":"Alys Pharmaceuticals se lance \u00e0 Gen\u00e8ve avec un investissement de USD 100 millions"}]},{"@type":"WebSite","@id":"https:\/\/staging.ggba.swiss\/en\/#website","url":"https:\/\/staging.ggba.swiss\/en\/","name":"Greater Geneva Bern area","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Person","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41","name":"Pierre-Yves Oehrli","url":"https:\/\/ggba.swiss\/fr\/author\/pierre-yves-oehrli\/"}]}},"_links":{"self":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts\/22733","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/comments?post=22733"}],"version-history":[{"count":1,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts\/22733\/revisions"}],"predecessor-version":[{"id":22735,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts\/22733\/revisions\/22735"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/media\/22730"}],"wp:attachment":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/media?parent=22733"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/categories?post=22733"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/tags?post=22733"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}